Han All Pharmaceutical Co., Ltd. (009420.KS) Acquires Global Rights To Nautilus Biotech's Protein Engineering Technology For Developing Novel Oral And Injectable Therapeutic Proteins
6/29/2009 1:49:11 PM
More...
|
Nautilus Biotech Receives FDA Approval for Phase 1 Clinical Trial in the USA for Oral Belerofon(R), its Long-Lasting, Interferon-Alpha Drug
5/21/2007 12:07:50 PM
More...
|
Nautilus Biotech Receives FDA Approval for Phase 1 Clinical Trial in the USA for Oral Belerofon(R), its Long-Lasting, Interferon-Alpha Drug
5/14/2007 11:29:55 AM
More...
|
Nautilus Biotech Closes EUR8.4 Million ($11.3 Million) Investment Funding
4/30/2007 1:48:36 PM
More...
|
Nautilus Biotech Begins Phase I Clinical Trial in the USA for Subcutaneous Belerofon(R), its Long-Lasting, Interferon-Alpha Drug
4/2/2007 11:04:51 AM
More...
|
Nautilus Biotech and Han All Pharmaceutical Co., Ltd. (009420.KS) Announce License Agreement to Develop Three Nautilus Biotech Products in South Korea
3/6/2007 1:15:53 PM
More...
|
Nautilus Biotech Announces IND Filing for Belerofon®, Its Oral, Long-lasting, Interferon-alpha Drug
3/2/2007 6:17:25 PM
More...
|
Wyeth (WYE) And Nautilus Biotech Announce Collaboration To Develop Hemophilia Therapies
2/5/2007 9:33:48 AM
More...
|
Nautilus Biotech And Creabilis Therapeutics Achieve Technical Milestone In Collaboration To Improve HMGB1 Box A For The Treatment Of Rage- And HMGB1-Related Pathologies
11/14/2006 10:41:43 AM
More...
|
Nautilus Biotech Announces IND Filing For Its Injectable Long-Lasting Interferon-alpha, BELEROFON(R)
10/10/2006 10:57:27 AM
More...
|
|